Sign up
Log in
Leerink Partners Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $24
Share
Listen to the news
Leerink Partners analyst Roanna Ruiz maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and lowers the price target from $25 to $24.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
Terms of Service·Privacy Policy·Data Disclaimer
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved